Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · IEX Real-Time Price · USD
6.60
-0.12 (-1.79%)
At close: May 17, 2024, 12:38 PM
6.78
+0.18 (2.73%)
After-hours: May 17, 2024, 4:00 PM EDT
Company Description
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases.
Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia.
Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp.
| Country | United States |
| Founded | 2020 |
| IPO Date | Sep 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Tiago Reis Marques M.D., Ph.D. |
Contact Details
Address: 2110 Narcissus Ct Venice, California 90291 United States | |
| Phone | (818) 422-6172 |
| Website | pasithea.com |
Stock Details
| Ticker Symbol | KTTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001841330 |
| CUSIP Number | 70261F103 |
| ISIN Number | US70261F2020 |
| Employer ID | 85-1591963 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD and Executive Chairman |
| Dr. Tiago Reis Marques M.D., Ph.D. | Chief Executive Officer and Director |
| Daniel H. Schneiderman | Chief Financial Officer |
| Dr. Graeme Currie Ph.D. | Chief Development Officer |
| Dr. Yassine Bendiabdallah Ph.D. | Chief Operating Officer and Head of UK Clinics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| Apr 2, 2024 | EFFECT | Notice of Effectiveness |
| Mar 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 29, 2024 | POS AM | Post-Effective amendments for registration statement |
| Mar 29, 2024 | 10-K | Annual Report |
| Jan 18, 2024 | 8-K | Current Report |
| Jan 2, 2024 | 8-K | Current Report |
| Dec 28, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 28, 2023 | 8-K | Current Report |